1-3 of 3
Su-Pin Choo
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Multi-omic Characterization of Pancreatic Ductal Adenocarcinoma Relates CXCR4 mRNA Expression Levels to Potential Clinical Targets

Open Access
Florian Kocher, Alberto Puccini, Gerold Untergasser, Agnieszka Martowicz, Kai Zimmer, Andreas Pircher, Yasmine Baca, Joanne Xiu, Johannes Haybaeck, Piotr Tymoszuk, Richard M. Goldberg, Angelica Petrillo, Anthony F. Shields, Mohamed E. Salem, John L. Marshall, Michael Hall, W. Michael Korn, Chadi Nabhan, Francesca Battaglin, Heinz-Josef Lenz, Emil Lou, Su-Pin Choo, Chee-Keong Toh, Silvia Gasteiger, Renate Pichler, Dominik Wolf, Andreas Seeber
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (22): 4957–4967.
https://doi.org/10.1158/1078-0432.CCR-22-0275
Published: 14 November 2022
View article titled, Multi-omic Characterization of Pancreatic Ductal Adenocarcinoma Relates CXCR4 mRNA Expression Levels to Potential Clinical Targets
Open the PDF for Multi-omic Characterization of Pancreatic Ductal Adenocarcinoma Relates CXCR4 mRNA Expression Levels to Potential Clinical Targets in another window
Includes: Supplementary data
Journal Articles

Real-Time Tumor Gene Expression Profiling to Direct Gastric Cancer Chemotherapy: Proof-of-Concept “3G” Trial

Free
Wei Peng Yong, Sun Young Rha, Iain Bee-Huat Tan, Su-Pin Choo, Nicholas L. Syn, Vivien Koh, Shi-Hui Tan, Bernadette Reyna Asuncion, Raghav Sundar, Jimmy Bok-Yan So, Asim Shabbir, Chee-Seng Tan, Hyo-Song Kim, Minkyu Jung, Hyun Cheol Chung, Matthew C.H. Ng, David Wai-Meng Tai, Ming-Hui Lee, Jeanie Wu, Khay Guan Yeoh, Patrick Tan
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (21): 5272–5281.
https://doi.org/10.1158/1078-0432.CCR-18-0193
Published: 01 November 2018
View article titled, Real-Time Tumor Gene Expression Profiling to Direct Gastric Cancer Chemotherapy: Proof-of-Concept “3G” Trial
Open the PDF for Real-Time Tumor Gene Expression Profiling to Direct Gastric Cancer Chemotherapy: Proof-of-Concept “3G” Trial in another window
Includes: Supplementary data
Journal Articles

Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with RAS-Mutated Hepatocellular Carcinoma

Free
Ho Yeong Lim, Philippe Merle, Karl Heinz Weiss, Thomas Yau, Paul Ross, Vincenzo Mazzaferro, Jean-Frédéric Blanc, Yuk Ting Ma, Chia Jui Yen, Judit Kocsis, Su Pin Choo, Wattana Sukeepaisarnjaroen, René Gérolami, Jean-François Dufour, Edward J. Gane, Baek-Yeol Ryoo, Markus Peck-Radosavljevic, Thong Dao, Winnie Yeo, Wisut Lamlertthon, Satawat Thongsawat, Michael Teufel, Katrin Roth, Diego Reis, Barrett H. Childs, Heiko Krissel, Josep M. Llovet
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (19): 4650–4661.
https://doi.org/10.1158/1078-0432.CCR-17-3588
Published: 01 October 2018
View article titled, Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with RAS-Mutated Hepatocellular Carcinoma
Open the PDF for Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with RAS-Mutated Hepatocellular Carcinoma in another window